Cladribine clinical trials
Also written Leustatin, 2-CdA, RWJ-26251 and Litak.
How each study uses Cladribine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Cladribine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Feb 1993 · LEUSTATIN · NDA 020229 (FDA, Drugs@FDA)
- European Union
- 14 Apr 2004 · Litak · EMEA/H/C/000504 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
81 studies that test it; most in 2016 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1996 | 1 |
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2016 | 9 |
| 2017 | 1 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 8 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 72
M.D. Anderson Cancer Center (11) · Fred Hutchinson Cancer Center (5) · University of Washington (5) · Merck KGaA, Darmstadt, Germany (3) · EMD Serono Research & Development Institute, Inc. (3) · Alliance for Clinical Trials in Oncology (3) · Sun Yat-sen University (3) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (2)
Often tested with
Tested in the same studies.
Cytarabine (33) · Mitoxantrone (15) · Rituximab (14) · Venetoclax (8) · Filgrastim (7) · Idarubicin (6) · Granulocyte Colony-Stimulating Factor (5) · Decitabine (5)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Cladribine is the comparator. A study of two new drugs counts under both.
- 1Cyclophosphamide · Haukeland University Hospital · next primary completion Nov 2026
- 1Antilymphocyte Serum · Haukeland University Hospital · next primary completion Nov 2026
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test Cladribine, phase 3 first.
- Jun 2027Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).Phase 2/3 · Institute of Psychiatry and Neurology, Warsaw
- Feb 2027CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaPhase 1 · Fred Hutchinson Cancer Center
- Apr 2027Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaPhase 2 · M.D. Anderson Cancer Center
- May 2027Cladribine Tablets After Treatment With Natalizumab (CLADRINA)Phase 4 · University of Texas Southwestern Medical Center
- Jun 2027Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaPhase 2 · M.D. Anderson Cancer Center
- Oct 2027Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLPhase 2 · OHSU Knight Cancer Institute
Studies
Open first, then newest update. How each study uses Cladribine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 82
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingPhase 1/2University of WashingtonNCT04797767Written as CladribineHow we know
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07311746Written as CladribineHow we know
- The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingPhase 2Uppsala UniversityNCT07517185Written as Sequential treatment with rituximab and cladribineHow we know
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03586609Written as CladribineHow we know
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingPhase 1Fred Hutchinson Cancer CenterNCT04375631Written as CladribineHow we know
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingPhase 2OHSU Knight Cancer InstituteNCT06504459Written as CladribineHow we know
- A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)Not yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07053020Written as Oral CladribineHow we know
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingPhase 2M.D. Anderson Cancer CenterNCT01515527Written as CladribineHow we know
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04047641Written as CladribineHow we know
- Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT00412594Written as CladribineHow we know
- A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsRecruitingPhase 2M.D. Anderson Cancer CenterNCT05365035Written as CladribineHow we know
- CAV Regimen for R/R Ph- B-ALLRecruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05657652Written as cladribine, cytarabine,venetoclaxHow we know
- Therapy Optimisation for the Treatment of Hairy Cell LeukemiaRecruitingPhase 2/3University of GiessenNCT02131753Written as Cladribine s.c. injection, HCL treatmentHow we know
- Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).RecruitingPhase 2/3Institute of Psychiatry and Neurology, WarsawNCT05961644Written as Cladribine Subcutaneous InjectionHow we know
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingPhase 2/3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05313958Written as CladribineHow we know
- A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine TabletsRecruitingPhase 4Keith Edwards, M.D.NCT04550455Written as Cladribine TabletsHow we know
- Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical StudyRecruitingPhase 3Ruijin HospitalNCT04880746Written as Cladribine combined with BEACHow we know
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisActive, not recruitingPhase 2/3North American Consortium for HistiocytosisNCT02205762Written as 2-chlorodeoxyadenosineHow we know
- Cladribine Tablets After Treatment With Natalizumab (CLADRINA)Active, not recruitingPhase 4University of Texas Southwestern Medical CenterNCT04178005Written as CladribineHow we know
- Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedPhase 2Medical College of WisconsinNCT03150004Written as Cladribine and Cytarabine (CLLDAC) RegimenHow we know
See all 82 studies that test Cladribine →
Given beside what is tested · 21 — Cladribine is usual care or a partner of the new treatment
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as CladribineHow we know
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingPhase 2M.D. Anderson Cancer CenterNCT03589729Written as CladribineHow we know
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Cladribine (CLAD)How we know
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingPhase 2/3M.D. Anderson Cancer CenterNCT04708054Written as CladribineHow we know
- Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLRecruitingPhase 1/2Stanford UniversityNCT06561152Written as Cladribine (CLAD)How we know
- CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLNot yet recruitingPhase 4Nanfang Hospital, Southern Medical UniversityNCT06763666Written as CladribineHow we know
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingPhase 3Sichuan UniversityNCT05466318Written as CladribineHow we know
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02250937Written as CladribineHow we know
- Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid LeukemiaCompletedPhase 1/2M.D. Anderson Cancer CenterNCT04848974Written as CladribineHow we know
- Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT02096055Written as CladribineHow we know
- Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnPhase 1Medical College of WisconsinNCT06007911Written as CladribineHow we know
- Effects of Cladribine Tablets on the PK of Microgynon®CompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03745144Written as CladribineHow we know
- Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampathCompletedPhase 2Goethe UniversityNCT00199030Written as CladribineHow we know
- Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownPhase 2Ge ZhengNCT05330364Written as CladribineHow we know
- Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1/2Washington University School of MedicineNCT02416908Written as CladribineHow we know
- Epacadostat, Cladribine and Cytarabine (ECC) in AMLWithdrawnPhase 1Insel Gruppe AG, University Hospital BernNCT03491579Written as CladribineHow we know
- Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin LymphomaStatus unknownPhase 2Sichuan UniversityNCT03602131Written as CladribineHow we know
- Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell LymphomaStatus unknownPhase 2Sichuan UniversityNCT03151876Written as CladribineHow we know
- R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaTerminatedPhase 2European Institute of OncologyNCT01446900Written as CladribineHow we know
- Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AMLCompletedPhase 1Washington University School of MedicineNCT01161550Written as CladribineHow we know
Showing 20 of 21.
As the comparator · 4 — what is tested is compared with Cladribine
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06561360Written as CladribineHow we know
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06965114Written as CladribineHow we know
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as CladribineHow we know
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingPhase 3Haukeland University HospitalNCT03477500Written as Cladribine PillHow we know
Codes
What other systems call Cladribine · ClinicalTrials.gg INT008593
- MeSH (NLM) D017338CladribineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 47M74X9YT5CLADRIBINEConfirmed FDA, NLM, Wikidata
- RxNorm 44157Confirmed FDA, Wikidata
- Wikidata Q414030cladribineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1336CladribineConfirmed FDA, Wikidata
- DrugBank DB00242One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017338 | Cladribine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 47M74X9YT5 | CLADRIBINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 44157 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414030 | cladribine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1336 | Cladribine | Confirmed FDA, Wikidata |
| DrugBank | DB00242 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.